Therapeutic breakthroughs: Our pipeline

Calluna Pharma, a powerful force in developing novel therapeutics for inflammatory and fibrotic diseases, was formed by the merger of two innovative biotech companies, Arxx Therapeutics and Oxitope Pharma BV. By combining expertise in targeting the root causes of these conditions, Calluna aims to revolutionize treatment options and significantly improve patient outcomes.

Our pipeline

Current status
Key milestone
PRODUCT
TARGET
Discovery
Pre-clinical
Phase 1
Phase 2

CAL101 Idiopathic pulmonary fibrosis (IPF)

S100A4

Initiating in 1H 2025*

CAL103 Chronic pipeline

OxPL

H2 2024

*In partnership with Lilly ExploR&D™